Dean Hartley 1 , Thomas Blumenthal 2 , Maria Carrillo 3 , Gilbert DiPaolo 4 , Lucille Esralew 5 , Katheleen Gardiner 6 , Ann-Charlotte Granholm 7 , Khalid Iqbal 8 , Michael Krams 9 , Cynthia Lemere 10 , Ira Lott 11 , William Mobley 12 , Seth Ness 9 , Ralph Nixon 13 , Huntington Potter 14 , Roger Reeves 15 , Marwan Sabbagh 16 , Wayne Silverman 17 , Benjamin Tycko 4 , Michelle Whitten 18 , Thomas Wisniewski 19
ADNI, Alzheimer's disease, Amyloid precursor protein, Animal models, Beta-amyloid, Biomarkers, Clinical trials, Cognitive assessment, DS-Connect, Dementia, Down syndrome, Drug discovery, Neuroimaging, Neuroinflammation, Tau, Trisomy 21, Ts65Dn, Workshop
In the United States, estimates indicate there are between 250,000 and 400,000 individuals with Down syndrome (DS), and nearly all will develop Alzheimer's disease (AD) pathology starting in their 30s. With the current lifespan being 55 to 60 years, approximately 70% will develop dementia, and if their life expectancy continues to increase, the number of individuals developing AD will concomitantly increase. Pathogenic and mechanistic links between DS and Alzheimer's prompted the Alzheimer's Association to partner with the Linda Crnic Institute for Down Syndrome and the Global Down Syndrome Foundation at a workshop of AD and DS experts to discuss similarities and differences, challenges, and future directions for this field. The workshop articulated a set of research priorities: (1) target identification and drug development, (2) clinical and pathological staging, (3) cognitive assessment and clinical trials, and (4) partnerships and collaborations with the ultimate goal to deliver effective disease-modifying treatments.